Tempus AI (TEM) and Stemline Therapeutics, a wholly-owned subsidiary of the Menarini Group, announced a new collaboration. The two companies ...

The Phase II portion is seeking to establish safety and efficacy of the company’s HER2 breast cancer therapy in combination ...

No improvement in overall survival (OS) was observed with palbociclib (Verzenio) plus endocrine therapy versus capecitabine ...

Biliary tract cancer is increasing in incidence and mortality across Europe, with more people under the age of 60 years old ...

AstraZeneca AZN stock has risen 8.6% in the past month, mainly due to mixed fourth-quarter results and a positive update from ...